• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes

byConstance Wu
August 7, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Urate reduction with allopurinol did not slow the decline of estimated glomerular filtration rate (eGFR) compared to the placebo treatment in patients with chronic kidney disease.

2. The urinary albumin:creatinine ratio was shown not to be significantly different between the treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Increased risk in the onset and progression of chronic kidney disease is associated with elevated serum urate levels. As a result of decreased excretion, the serum urate level increases linearly as the GFR decreases. However, it is unclear whether elevated serum urate levels exacerbate kidney disease progression or if it acts as an indirect marker for decreased kidney function. As such, this study tested whether the serum urate reduction with allopurinol would reduce the decline in the eGFR in patients with chronic kidney disease. The study determined patients with urate lowering therapy with allopurinol did not have a slower decline in eGFR compared to the patients in the placebo treatment group. This study had several limitations. Of note, the trial used a serum creatinine-based equation to calculate eGFR, which was not as sensitive in detecting GFR changes. Also, during the trial, a high percentage of patients discontinued the treatment regimen, which led to an underpowered study. Nonetheless, this study was strengthened by the prolonged follow-up period for both treatment groups.

Click to read the study, published today in NEJM

In-Depth [randomized controlled trial]: This randomized control trial enrolled 369 patients in a multicenter study from 31 sites in Australia and New Zealand. Patients who were included were at least 18 years of age, had evidence of stage 3 or 4 kidney disease and an albumin/creatinine ratio of 265 or greater. The exclusion criteria for the study included history of gout and allopurinol insensitivity. The patients were randomized in a 1:1 ratio to receive either oral placebo or allopurinol. The primary outcome was the change in eGFR from baseline to the end of the trial at 104 weeks. The change in eGFR did not significantly differ between the allopurinol group (-3.33 mL per minute per 1.73m2 per year; 95% confidence interval [CI], -4.11 to -2.55) and placebo group (-3.23 mL per minute per 1.73m2 per year; 95% CI, -3.98 to -2.47). The mean difference for the eGFR changes amongst both groups was -0.10 mL per minute per 1.73m2 per year (95% CI, -1.18 to 0.97; P=0.85). At week 104, the mean serum urate level, in the allopurinol group, decreased to 5.3 mg per deciliter (95% CI, 5.1 to 5.6), while the mean serum urate level, in the placebo group, decreased to 8.2 mg per deciliter (95% CI, 7.9 to 8.4). Furthermore, there was no significant difference in the urinary albumin:creatinine ratio between the two group (between-group difference, -9%; 95% CI, -24 to 10). Taken together, the reduction of serum urate with allopurinol did not slow the decline of eGFR in patients with chronic kidney disease.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

Risk of chronic kidney disease progression may be greater amongst patients with obstructive sleep apnea

Wellness Check: Sleep

Tags: allopurinalCKDkidneyurate
Previous Post

Trends in antihypertensive medication use among individuals with a history of stroke and hypertension

Next Post

Characteristics and strength of evidence of covid-19 studies registered on clinicaltrials.gov

RelatedReports

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

April 14, 2022
CPAP may not decrease cardiovascular events in sleep apnea
Nephrology

Risk of chronic kidney disease progression may be greater amongst patients with obstructive sleep apnea

March 14, 2022
Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

March 10, 2022
#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients
StudyGraphics

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

October 13, 2021
Next Post
Hydroxychloroquine not beneficial for early, mild COVID-19

Characteristics and strength of evidence of covid-19 studies registered on clinicaltrials.gov

#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin

#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

Further evidence that Zika virus disease associated with brain and eye birth defects

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
  • #VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.